Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARTH EXPLORER 2: Mavrilimumab vs Golimumab in RA
NCT01715896Phase 2Completed
- Sponsor
- MedImmune
- Start
- Mar 2013
- Primary completion
- Nov 2014
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of mavrilimumab in rheumatoid arthritis (RA), sponsored by MedImmune. Started Mar 2013; status: completed.
02
Drugs
mavrilimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01715896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01715896.